CD8A and melanoma: Importantly, our results suggested that the BG34-200 treatment could improve systemic T cell priming because TdLN-derived CD8+ T cell frequency was higher on day 0 and melanoma-specific T cells were more proliferative on day 7 (Figure 5D).